VSN 16R

Drug Profile

VSN 16R

Alternative Names: VSN-16R

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Canbex Therapeutics; University College London
  • Developer Canbex Therapeutics
  • Class Small molecules
  • Mechanism of Action Cannabinoid receptor modulators; G-protein-coupled receptor 55 modulators; Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Muscle spasticity

Most Recent Events

  • 01 Oct 2017 Canbex Therapeutics completes a phase II trial in Muscle spasticity in United Kingdom (NCT02542787)
  • 24 Feb 2015 Ipsen signs an option agreement to acquire Canbex Therapeutics
  • 24 Feb 2015 Canbex plans a phase IIa trial for Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top